PolyPeptide

CEO Raymond De Vré
Head IR Michael Stäheli

ZKB Analyst: Daniel Buchta

Group meeting, One-on-one, Small group meeting

PolyPeptide Group AG operates as a biotechnology company. The Company focuses on producing proprietary and generic GMP grade peptides for the pharmaceutical and biotechnology industry. PolyPeptide Group serves customers worldwide.

Join event

Get first hand information about Switzerland's leading companies from their leaders themselves.

Get in touch

The following content is directed only to persons that meet below qualifications and have relevant professional experience and should not be acted on or relied on by other persons.

I'm acting for a legal entity with its registered office in:

Switzerland

which qualifies as institutional client according to Article 4(4) of the Federal Act on Financial Services (FinSA) or as a professional client according to Article 4(3) FinSA.

United Kingdom

the legal entity is authorised by the PRA or FCA or qualifies as any other investment professional falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005

or the legal entity has a share capital or net assets of at least £5 million or qualifies for other grounds as a high net worth company according to Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005.

Others

I am a natural person (retail client) or the company I'm acting for doesn't fit one of the categories above.

Confirm

Your web browser is out of date

Update your browser for more security, speed and the best experience.

Update my browser Continue

PolyPeptide

PolyPeptide

Date & Location

Join event

Need help?